Disposition of the antipsychotic agent CI-1007 in rats, monkeys, dogs, and human cytochrome P450 2D6 extensive metabolizers: Species comparison and allometric scaling

Drug Metabolism and Disposition

Volumn 26, Issue 10, 1998, Pages 982-988

  Feng, Meihua Rose ^a   Loo, Joseph ^b   Wright, Jonathan ^b  

^a PFIZER INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 4 PHENYL 1 [(3 PHENYL 3 CYCLOHEXEN 1 YL)METHYL]PYRIDINE; NEUROLEPTIC AGENT; PD 147693; PD 149394; PD 155144; PD 163249; PD 163637; UNCLASSIFIED DRUG;

ALLOMETRY; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DOG; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISPOSITION; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; MONKEY; NONHUMAN; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SCINTILLATION COUNTING; SPECIES DIFFERENCE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ANTIPSYCHOTIC AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2D6; DOGS; HUMANS; MACACA FASCICULARIS; MALE; RATS; RATS, WISTAR; SPECIES SPECIFICITY;

ANIMALIA; CANIS FAMILIARIS;

EID: 0031725042     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Altman PL and Dittmer DS (1974) Biology Data Book, ed 2, vol 3, pp 1704-1706, Federation of American Societies for Experimental Biology, Bethesda, MD.
2. Bernareggi A and Rowland M (1991) Physiologic modeling of cyclosporin kinetics in rat and man. J Pharmacokinet Biopharm 1:21-50.
3. Boxenbaum H (1980) Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance in extrapolation of data to benzodiazepines and phenytoin. J Pharmacokinet Biopharm 8:165-176.
4. Davis B and Morris T (1993) Physiological parameters in laboratory animals and humans. Pharm Res 10:1093-1095.
5. Dedrick RL and Forrester DD (1973) Blood flow limitation in interpreting Michaelis constants for ethanol oxidation in vivo. Biochem Pharmacol 22:1133-1140.
6. Evans GH, Niles AS and Shand DG (1973) The disposition of propranolol. III. Decreased half-life and volume of distribution as a result of plasma protein binding in man, monkey, dog, and rat. J Pharmacol Exp Ther 186:114-122.
7. Feng MR, Atherton J, Knoll S, Strenkoski C and Wright DS (1997a) Determination of two Q-1007 sulfate metabolites in monkey plasma and urine. J Chromatogr B 693:159-166.
8. Feng MR, Bezek S, Gandhi A, Strenkoski C, Wright J, Woolf T and Wright D (1994) Pharmacokinetics and metabolism of CI-1007 and analogues in rats and in isolated rat hepatocytes. Pharm Res 10:S-347.
9. Feng MR, Brown R, Underwood B, Posvar EL and Eldon MA (1998) Pharmacokinetics of CI-1007, an investigational antipsychotic drug, in cytochrome P450 2D6 extensive metabolizers. Clin Pharm Ther 2:185.
10. Feng MR, Corbin A, Wang Y, Christoffersen C, Wiley J, Strenkoski C, Tucker E, Ninteman F, Heffner T and Wright D (1997b) Pharmacokinetics and pharmacodynamics of a potential antipsychotic agent, CI-1007, in rats and monkeys. Pharm Res 14:329-336.
11. Feng MR, Siersma P Strenkoski C and Wright D (1995) Sensitive high performance liquid chromatographic method for CI-1007 and its active metabolite PD 147693 in monkey plasma. J Chromalogr B 665:193-199.
12. Feng MR, Strenkoski C, Parker T and Wright DS (1993) Oral absorption of PD 143188 in rats and monkeys. Pharm Res 10:S-320.
13. Meltzer L, Christoffersen C, Corbin A, Ninteman F, Serpa K, Wise L and Heffner T (1995) CI-1007, a dopamine partial agonist and potential antipsychotic agent. II. Neurophysiological and behavioral effects. J Pharmacol Exp Ther 274:912-920.
14. Mordenti J (1985) Forecasting cephalosporin and monobactam antibiotic half-lives in humans from data collected in laboratory animals. Antimicrob Agents Chemother 27:887-891.
15. Mordenti J (1986) Man versus beast: pharmacokinetic scaling in mammals. J Pharm Sci 75:1028-1040.
16. Obach R, Baxter J, Liston T, Silber B, Jones B, MacIntyre F, Rance D and Wastall P (1997) The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 1:46-58.
17. Ohnhaus EE and Locher JT (1975) Liver blood flow and blood volume following chronic phenobarbitone administration. Eur J Pharmacol 31:161-165.
18. Pugsley T, Davis M, Akunne H, Cook L, Whetzel S, Mackenzie R, Shin Y, Lewen V, Demattos S, Caprathe B, Wright J, Jaen J, Wise L and Heffner T (1995) CI-1007, a dopamine partial agonist and potential antipsychotic agent. I. Neurochemical effects. J Pharmacol Exp Ther 274:898-911.
19. Reuning RH and Gerates DR (1986) Digoxin, in Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring (Evan WE, Schentag JJ and Jusko WJ eds) pp 570-623, Applied Therapeutics, Inc., Spokane, WA.
20. Sinz M, Michniewicz B and Woolf T (1995) Metabolic and species comparison of the antipsychotic agent CI-1007 using microsomes, hepatocytes, and purified enzymes. Proceedings of the 4th North American ISSX Meeting 8:118.
21. Sramek J, Eldon M, Posvar E, Feng MR, Jhee S, Hourani J, Sedman A and Cutler N (1998) Initial safety, tolerability, pharmacodynamics and pharmacokinetics of CI-1007 in schizophrenic patients. Psychopharmacol Bull 1:93-99.
22. Wright J, Downing D, Feng MR, Hayes R, Heffner T, Mackenzie R, Meltzer L, Pugsley T and Wise L (1995) The identification, characterization, and pharmacological profile of three metabolites of (R)-(+)-1,2,3,6-tetrahydro-4-phenyl-1-[(3-phenylcyclohexen-1-yl)methyl]pyridine, a dopamine autoreceptor agonist and potential antipsychotic agent. J Med Chem 38: 5007-5014.
23. Yates MS, Hileg CR, Roberts PJ, Back DJ and Crawford FE (1978) Differential effects of hepatic microsomal enzyme inducing agents on liver blood flow. Biochem Pharmacol 27: 2617-2621.